Literature DB >> 12195877

Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study.

Peter Lanbeck1, Inga Odenholt, Otto Paulsen.   

Abstract

Intravenous administration of antibiotics is a known risk factor for infusion phlebitis. We have previously demonstrated differences in cell toxicity for 4 antibiotics. Clinical experience indicates that antibiotics differ in their tendency to cause phlebitis. The present study was done prospectively on 550 patients with 1386 peripheral venous catheters. The incidence of phlebitis was 18.5% with antibiotics and 8.8% without (odds ratio 2.34). Dicloxacillin (odds ratio 5.74) and erythromycin (odds ratio 5.33) had the greatest tendency to cause phlebitis in univariate, multivariate and Cox regression analyses. Benzylpenicillin, cefuroxime and cloxacillin were also associated with a greater risk of phlebitis, whereas ampicillin, imipenem/cilastatin, clindamycin, netilmicin and vancomycin were not. Other risk factors were the site of insertion and age 51-60 y. Medication with warfarin was found to be protective, but not with aspirin. Treatment with low molecular weight heparin reduced the risk of phlebitis, but the difference was not significant. With regard to when antibiotics were given, the day-specific risk increased between Days 1 and 2, but no further on subsequent days. The hypothesis that antibiotics differ in their tendency to cause phlebitis was confirmed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195877     DOI: 10.1080/00365540110080908

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  12 in total

1.  Intravascular catheter related infections in children admitted on the paediatric wards of Mulago Hospital, Uganda.

Authors:  Patricia Nahirya; Justus Byarugaba; Sarah Kiguli; Deogratias Kaddu-Mulindwa
Journal:  Afr Health Sci       Date:  2008-12       Impact factor: 0.927

2.  Role of surfactant and pH on dissolution properties of fenofibrate and glipizide--a technical note.

Authors:  Shahla Jamzad; Reza Fassihi
Journal:  AAPS PharmSciTech       Date:  2006-04-07       Impact factor: 3.246

3.  Endothelial Cell Toxicity of Vancomycin Infusion Combined with Other Antibiotics.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

5.  Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study.

Authors:  D A Barr; L Semple; R A Seaton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-12       Impact factor: 3.267

6.  Postoperative Acute Superficial Thrombophlebitis, an interesting case.

Authors:  Soumya Sarkar; Aswini Kuberan; Lakshmi N Yaddanapudi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-07-15

Review 7.  Infection risks associated with peripheral vascular catheters.

Authors:  Li Zhang; Siyu Cao; Nicole Marsh; Gillian Ray-Barruel; Julie Flynn; Emily Larsen; Claire M Rickard
Journal:  J Infect Prev       Date:  2016-07-06

8.  Safety of topical vancomycin powder in neurosurgery.

Authors:  Kalil G Abdullah; H Isaac Chen; Timothy H Lucas
Journal:  Surg Neurol Int       Date:  2016-12-05

9.  Adverse events related to intravenous antibiotic therapy: a prospective observational study in the treatment of infective endocarditis.

Authors:  Débora Holanda Gonçalves De Paula; Bernardo Rangel Tura; Cristiane da Cruz Lamas
Journal:  BMJ Open       Date:  2012-10-26       Impact factor: 2.692

10.  Safe administration of vancomycin through a novel midline catheter: a randomized, prospective clinical trial.

Authors:  Jona V Caparas; Jian-Ping Hu
Journal:  J Vasc Access       Date:  2014-04-08       Impact factor: 2.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.